Stem Cell Research Advancement Act of 2011

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research.

Client expense: $86,377 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $100,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research.

Client expense: $101,698 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $100,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

HR 2700, Global Autism Assistance Act of 2011: support for educational grant program related to autism spectrum disorders. S 1094, Combating Autism Reauthorization Act: support for autism research grant program. H. Res. 1219, HR 1217, To Repeal the Prevention and Public Health Fund: support for retention of the establishment of and appropriating funds for the Prevention and Public Health Fund in the Patient Protection and Affordable Care Act. HR 2205, Ending Defensive Medicine and Encouraging Innovative Reforms: support for prompt and fair resolution of medical disputes, enhancing quality of care, and ensuring patient access. HR 2376, Stem Cell Research Advancement Act of 2011: support for federal funding of human stem cell research. HR 2625, Research Participants Protection Modernization Act of 2011: support for protection of human subjects in research and for a reduction in regulatory burden, as appropriate.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $90,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Thrombosis Sickle Cell Disease Clinical Trials Regulations Electronic Health Records (EHR) Comparative Effectiveness Research Hematology/Oncology treatment Issues General Hematology Public Health and Research Issues Embryonic Stem Cell Research and Regenerative Medicine Hematology and Oncology Drug Research and Approval Issues, Drug Shortage Issues H.R. 2376, the Stem Cell Research Advancement Act of 2011 S. 296, the Preserving Access to Life-Saving Medications Act H.R. 2245, the Preserving Access to Life-Saving Medications Act Hematology workforce issues

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Nuclear Regulatory Commission (NRC), SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $90,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 1862, Regenerative Medicine Promotion Act of 2011 H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act H.R. 2376, Stem Cell Research Advancement Act of 2011 H.R. 2960, National Diabetes Clinical Care Commission Act H.R. 2969/S. 1454, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011

Client expense: $40,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research.

Client expense: $103,704 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Thrombosis Sickle Cell Disease Clinical Trials Regulations Electronic Health Records (EHR) Comparative Effectiveness Research Hematology/Oncology treatment Issues General Hematology Public Health and Research Issues Embryonic Stem Cell Research and Regenerative Medicine Hematology and Oncology Drug Research and Approval Issues, Drug Shortage Issues H.R. 2376, the Stem Cell Research Advancement Act of 2011 S. 296, the Preserving Access to Life-Saving Medications Act H.R. 2245, the Preserving Access to Life-Saving Medications Act Hematology workforce issues

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Nuclear Regulatory Commission (NRC), SENATE

H.R. 2376 Stem Cell Research Advancement Act of 2011 H.R. 1862 Regenerative Medicine Promotion Act of 2011 H.R. 2969/S.1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011

Client expense: $40,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

See next page. Have continued to advocate against the repeal of the 2010 Affordable Care Act. Have met with Congressional staff and signed letters of support for the ACA and full enactment of its various provisions. Participated in discussion with DHHS of data development on health disparities and capturing information on people with disabilities as a disparity population criteria. Continued to reinforce with the DHHS Secretary and the Quality Measures Workgroup of the Health Information Technology Policy Committee better ways to address the health care needs of people with disabilities within the new clinical quality measures to be developed to leverage the evolving health IT infrastructure and decrease disability health disparities. Supported HR 1862 the National Regenerative Medicine Strategy legislation. Supported HR 2376 the Stem Cell Research Advancement Act. Participated in meetings of FDA-sponsored MDUFA III Stakeholders Group. Endorsed group letter to FDA Center for Devices and Radiological Health to comment on the Institute of Medicine (IOM) report on "Medical Devices and the Public Health" and recommend ways to strengthen the 510 (k) new device review process. Joined with 70 other organizations in a letter to the Senate HELP Committee urging reauthorization of the Lifespan Respite Care program. Participated in letters from the NDLA and CCD to the President urging implementation of the CLASS long-term services an supports insurance program. Participated in briefing with Centers for Disease Control and Prevention (CDC) officials on Year One progress the CDC Disability and Health Work Group. See Budget/Appropriation, Medicaid, and Medicare.

Client expense: $80,000 · Firm income: Not reported

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research. Contacts in support of inclusion of "Weldon" language to bar issuance of patents on human organisms reported under CPT (Copyright/Patent/Trademark). See also CPT (Copyright/Patent/Trademark) regarding contacts on H.R. 1249.

Client expense: $86,109 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research. Contacts in support of Section 33 of H.R. 1249, to bar issuance of patents on human organisms (also reported under Copyright/Patent/Trademark).

Client expense: $113,589 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

HR 2700, Global Autism Assistance Act of 2011: support for educational grant program related to autism spectrum disorders. S. 1094, Combating Autism Reauthorization Act: support for autism research grant program. H.Res. 1219, HR 1217, To Repeal the Prevention and Public Health Fund: support for retention of the establishment of and appropriating funds for the Prevention and Public Health fund in the Patient Protection and Affordable Care Act. HR 2205, Ending Defensive Medicine and Encouraging Innovative Reforms: support for prompt and fair resolution of medical disputes, enhancing quality of care, and ensuring patient access. HR 2376, Stem Cell Research Advancement Act of 2011: support for federal funding of human stem cell research. HR 2625, Research Participants Protection Modernization Act of 2011: support for protection of human subjects in research and for a reduction in regulatory burden, as appropriate.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2376 Stem Cell Research Advancement Act of 2011 H.R. 1862 Regenerative Medicine Promotion Act of 2011

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.XX (introduced 7/20/11- no bill # yet)/S. 425, "The National Neurological Diseases Surveillance System Act," all sections; " all sections relating to the National Institutes of Health (NIH), Cures Acceleration Network at NIH, the National Center for Advancing Translational Sciences" "Department of Defense Appropriations," sec. related to the Neurotoxin Exposure Treatment Parkinson's Research (NETPR) program; H.R 2376 Stem Cell Research Advancement Act of 2011 all sections; CMS Plan Year 2012 Draft Call Letter forMedicare Part D; "Department of Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2012," all sections related to FDA; Prescription Drug User Fee Act (PDUFA) V (not yet related to specific legislation); H.R.1546/S.829, "the Medicare Access to Rehabiltational Services Act of 2011", all sections.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Thrombosis Sickle Cell Disease Clinical Trials Regulations Electronic Health Records (EHR) Comparative Effectiveness Research Hematology/Oncology treatment Issues General Hematology Public Health and Research Issues Embryonic Stem Cell Research and Regenerative Medicine Hematology and Oncology Drug Research and Approval Issues, Drug Shortage Issues H.R. 2376, the Stem Cell Research Advancement Act of 2011 S. 296, the Preserving Access to Life-Saving Medications Act H.R. 2245, the Preserving Access to Life-Saving Medications Act H.R. 640, the Bone Marrow Failure Disease Research and Treatment Act S.Res. 172, resolution designating May 2011 as National Cancer Research Month

Client expense: $30,000 · Firm income: Not reported

See following page. Have continued to advocate against the repeal of the 2010 Affordable Care Act. Have met with Congressional staff and signed letters of support for the ACA and full enactment of provisions included in it. Participated in HHS discussion of data development on health disparities. Recommended to the DHHS Secretary and the Quality Measures Workgroup of the Health Information Technology Policy Committee ways to address the health care needs of people with disabilities within the new clinical quality measures to be developed to leverage the evolving health IT infrastructure and decrease disability health disparities. Supported HR 1862 the National Regenerative Medicine Strategy legislation. Supported HR 2376 the Stem Cell Research Advancement Act.

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA), State, Dept of (DOS), Veterans Affairs, Dept of (VA), White House Office

Stem Cell Research Policy HR2376 Stem Cell Research Advancement Act

Client expense: $100,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Contacts in opposition to H.R. 2376, DeGette-Dent bill to promote federal funding of the types of stem cell research that require the killing of human embryos, including federal funding of human clone-and-kill research. Contacts in support of inclusion of "Weldon" language to bar issuance of patents on human organisms reported under CPT (Copyright/Patent/Trademark). See also CPT (Copyright/Patent/Trademark) regarding contacts on H.R. 1249.

Client expense: $45,779 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE